ClinicalTrials.gg
CompletedNCT05515497Bmt4me 2Updated Oct 27, 2026Results posted

BMT4me: Post-HSCT Medication Adherence mHealth App

An interventional study of BMT4me 2.0 app in Stem Cell Transplant, Adherence, Medication and Digital Health, sponsored by Micah Skeens. Completed at 1 site in United States. Open to participants aged 0 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Micah Skeens · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 27, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
0 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Medication Adherence with a site in United States — 59 open to participants now, 74 under way, 1 of them phase 3. Medication Adherence · United States.

Enrollment
286th of 422
50 · median 96
Started
2022
with 27 others
No phase
368 of 463
53 open now
Registered
373rd of 463
by date

Among the 463 studies in Medication Adherence with a site in United States, this one is the 286th largest by enrollment of the 422 interventional ones that give a count, is one of 28 that started in 2022, is one of 368 with no phase, and was the 373rd registered.

Medication Adherence

943 studies on the registry are indexed under Medication Adherence; 162 are open to participants now.

Browse Medication Adherence studies →

Open to participants now

59 of the 463 studies in Medication Adherence with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 81 Medication Adherence studies recruiting now, 52 (64%) set no upper age limit and 21 (26%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.

This study: 0 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Medication Adherence with a site in United States, or all of them as a file.
02

Study summary

This is a mixed methods, prospective longitudinal pilot RCT to evaluate the 1) acceptability of a newly developed mHealth app (BMT4me), 2) the feasibility of enrolling and retaining caregivers of children in the acute phase post-HSCT, and 3) the potential efficacy of an mHealth app on adherence to immunosuppressants in post-HSCT children discharged during the acute phase.

Read the detailed description

In the United States, poor adherence accounts for up to 70% of all medication-related hospital admissions, resulting in $100 billion in healthcare costs annually Adherence rates have been reported as low as 0% in pediatric patients. Reasons for non-adherence are multifactorial. The most important determinants of non-adherence are consistently documented as complexity and duration of treatment regimens, as well as forgetfulness. Thus, children undergoing difficult hematopoietic stem cell transplants (HSCT) that require medication indefinitely are at high risk for medication non-adherence.

Only 4 published studies exist regarding adherence in pediatric HSCT. None address adherence to immunosuppressant medication, nor are they RCTs. Second, the complexity of most interventions for adherence is counter to the geographic, resource, and time constraints families of chronically ill children face. Adherence interventions based on conventional behavior theory have been cumbersome for families already stressed due to chronic illness. BE design is a significant paradigm shift to a simpler, less onerous approach that can engage those patients and families that would otherwise forego complicated adherence interventions. Although mHealth adherence apps are a widely available, simple, and innovative approach to addressing these problems, a third gap relates to poor usability. For example, a recent review of pediatric adherence apps found that none identified individual barriers to adherence, and nearly all were designed for adults. Thus, there is an urgent need to develop and evaluate innovative, accessible, and evidence-based approached to adherence among children receiving HSCT to prevent morbidity and mortality from GVHD.

The impact of non-adherence on clinical outcomes is largely unknown in pediatric HSCT. poor adherence is generally associated with adverse outcomes, including complications, hospital admissions, and even death. The societal burden of cancer care and HSCT is substantial and likely to increase based on the growing number of transplants each year. Clinicians and researchers have focused on GVHD prevention to minimize unnecessary treatment-related deaths. Acute GVHD develops in the first 100 days post-transplant. Children that develop acute GVHD have a 30% to 50% chance of survival. Morbidity and mortality due to GVHD can be decreased through prophylactic use of immunosuppressants. Although these medications are costly and produce unpleasant side effects, adherence is critical to decrease complications, reduce readmissions, and ultimately increase quality of life and survival.

Adherence is complex, but ultimately, the final common pathway to adherence is human behavior. In pediatrics, adherence is largely dependent on parents. As the primary caregivers, they are responsible for ensuring children receive the prescribed therapy correctly. In a high-risk HSCT population, caregivers are isolated with their child due to infection risk and must manage challenging treatment regimens at home, often with limited time and support. Complex behavioral interventions, typically employed to address adherence, are difficult to deliver and manage in the context of these daily tasks. Alternatively, behavioral economics (BE) theory suggests that small "nudges" can produce and sustain behavior change. A BE approach is a significant paradigm shift and assumes decision-making can be influenced through low-intensity interventions to lead patients to optimal choices. Improved adherence to medication and exercise programs using BE designed interventions in adults have been positive. Within pediatrics, BE has been successful in reducing childhood obesity, increasing vaccination rates, and improving adherence rates to infant HIV medications.

03

Conditions studied

  • Stem Cell Transplant
  • Adherence, Medication
  • Digital Health

Browse trials for

Keywords

  • Adherence
  • mHealth
  • Stem Cell transplant
  • Immunosuppression
  • Digital Health
  • Pediatrics
04

Who can participate

Ages eligible
0 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of caregivers must be a) 0 to 21 years of age; b) receiving for an transplant or anti-infective for an autologous transplant; c) discharged prior to Day 100 or completion of immunosuppression taper, and d) residing with the primary caregiver that enrolls on the study.
  • Primary caregivers must be: d) English-speaking; and e) have an iOS or Android capable cellular device.

Exclusion criteria

Exclusion Criteria:

  • Adults unable to consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    BMT4me 2.0 Intervention Group

    The intervention group will be receiving the BMT4me 2.0 app at discharge as the primary intervention.

    Device: BMT4me 2.0 app

  • No intervention
    BMT4me 2.0 Control Group

    The control group will be receiving usual care at discharge. These participants will not be receiving the BMT4me 2.0 app.

Interventions

  • DeviceBMT4me 2.0 app

    The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.

06

What researchers measure

Primary outcomes

  1. Momentary Event Monitoring System (MEMS) Caps

    MEMS Caps collect daily data via a micro-electronic circuit that registers the opening and closing of the threaded pill bottle. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected either at weekly or monthly from participants at their visits in the BMT clinic as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit.53,54 An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.55

    Time frame: Baseline to day 100

  2. Medication Adherence Measure (MAM)

    The MAM is semi-structured interview specific to pediatrics, conducted with the parent, to obtain an individual score in each module. The score is represented in percentages of the number of required doses. A total summary score can be calculated across all medications, as well as separately. This allows for quantification of the degree of adherence on a continuum.

    Time frame: Baseline to day 100

  3. System Usability Scale

    The SUS is a 10-item questionnaire routinely used to evaluate the functionality and acceptability of mHealth apps. Items are rated on a 5-point scale and scores range from 0 to 100. A higher score indicates better usability. Reliability and validity have been well established. A score of \> 68% is considered above average.

    Time frame: Exit (Day 100)

  4. Posttransplant Perception Survey

    The posttransplant perception survey is a self-report clinical assessment tool adapted from the kidney transplant population for this trial. The tool contains 7 questions asking participants to report on their views about their child's health and perceptions post-transplant. Questions are rated on a 5-point Likert scale. The first three questions related to worry about child's health and are considered the "Worry" subscale which ranges from 3 to 15, with higher scores indicating more worry. The second four questions relate to the understanding of child's health and are considered the "Understanding" subscale. Scores range from 4 to 20, where higher scores indicate less understanding.

    Time frame: Baseline (Week 0) to 100 Days Post Transplant

  5. Barrier Assessment Tool

    The Barrier Assessment Tool (BAT) is a self-report clinical assessment tool. The tool contains 14 commonly endorsed barriers with a checkbox next to each item. Domains include logistical issues (e.g., forgetting, inconvenience), ingestion difficulties (e.g., swallowing, taste), efficacy (e.g., feel I don't need it), financial difficulties, regimen characteristics (e.g., too many medications, side effects), and patient-specific issues (e.g., refusal by child, embarrassment). A sum total of the number of barriers is calculated, as well as concordance between caregiver and patient report. In the feasibility study, the average concordance between caregiver and patient report of each barrier (n=48) was 0.299.53 The total barrier score will be used. A sum total of 0 to 14 could be calculated, with higher scores indicating more barriers.

    Time frame: Baseline (Week 0) to 100 Days Post Transplant

  6. Caregiver Satisfaction

    Satisfaction will be assessed via semi-structured interviews and an electronic version of the Caregiver Satisfaction Questionnaire with caregivers. Caregivers will be asked for feedback regarding participation in the intervention, benefit, burden, barriers, suggested modifications, and overall satisfaction. Suggested modifications to the app and advice to the healthcare team will also be solicited. Due to the qualitative nature of the interview, caregiver responses cannot be scored but will be coded for themes. Nine questions are included on the Caregiver Satisfaction Questionnaire and responses are on a 1 to 4 Likert scale. A total sum score ranges from 9 to 36, with higher scores indicating more satisfaction.

    Time frame: Exit (Day 100)

  7. Pediatric Quality of Life Inventory (PedsQL) Version 4.0

    Caregivers completed the Pediatric Quality of Life Inventory (PedsQL) every three weeks (at week 3, week 6, and week 9). The PedsQL has 4 domains related to physical, emotional, social, and school functioning totaling 23 items. Items are rated on a 3 or 5-point Likert scale. All items (23) are summed to a total PedsQL score. Total scores range from 0 - 100, with higher scores indicating higher quality of life. Versions are based on child age: (a) 5-7, (b) 8-12 and, (c) 13-18 years old.

    Time frame: Week 3, Week 6, and Week 9

  8. Medy Remote Patient Management (RPM) Medication Box by Vaica

    Medy RPM collects daily data via an NFC reader. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected monthly from participants as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit. An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.

    Time frame: Baseline to day 100

  9. Wisepill

    Wisepill is a pillbox that collects data on medication usage through the internet. The Wisepill model utilized was evriMED1000. This data was collected as a direct measure of adherence. The evriMED1000 pillbox recorded when the lid was opened and closed and uploaded data in real time into a cloud-based server, where data was retrieved after study exit.

    Time frame: Baseline to day 100

Secondary outcomes

  1. Medication Level Variability Index (MLVI)

    Medication Level Variability Index (MLVI) measures the variation of tacrolimus levels in the blood of a patient over time. Higher variability has been associated with increased risk of poor outcomes following solid organ transplant, with limited findings suggesting a similar trend in HCT. MLVI is calculated using the standard deviation of three or more medication levels. The range of scores is not consistent, but MLVI typically falls between 0-10, with higher scores indicating higher variability (and therefore higher risk of complications). There are clinically significant cutoff scores for solid organ transplant populations; an MLVI of 3 or higher is generally considered to be a high risk. Both continuous and dichotomous scores were used in this analysis.

    Time frame: Weekly until day 100

  2. Number of Participants With Graft vs. Host Disease (GVHD)

    GVHD will be assessed on the international standard acute GVHD grading and staging scale. Provider grading will be per organ system on a 1-4 scale, with an overall score given weekly.

    Time frame: Weekly until day 100

  3. Number of Participants With Readmissions

    Readmission rates will be determined by the number of admissions requiring greater than a 24-hour stay within the first 100 days after discharge. Reason for readmission will be recorded and based on the EMR discharge diagnosis. In addition, a sub-analysis of readmissions within the first 30 days after initial discharge post-HSCT will be completed.

    Time frame: Weekly until day 100

  4. Caregiver Education Level

    Caregiver reported education level

    Time frame: Baseline (Week 0)

  5. Annual Household Income

    Caregiver reported annual household income

    Time frame: Baseline (Week 0)

07

Results

Posted Oct 27, 2026
Limitations and caveats
Application malfunctioning and changes in electronic adherence monitoring may have impacted the results.

Participant flow

Participants were approached in-person at inpatient rooms post BMT, prior to discharge. One participant was recruited per family, either the caregivers themselves or the adolescent who self-managed their medication. We refer to all participants as caregivers.

Participant flow — Overall Study
MilestoneBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Started2426
Completed2223
Not completed23

Outcome measures

PrimaryMomentary Event Monitoring System (MEMS) Caps

MEMS Caps collect daily data via a micro-electronic circuit that registers the opening and closing of the threaded pill bottle. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected either at weekly or monthly from participants at their visits in the BMT clinic as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit.53,54 An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.55

Time frame:
Baseline to day 100
Reported as:
Mean · Percent
Momentary Event Monitoring System (MEMS) Caps
PercentBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Momentary Event Monitoring System (MEMS) Caps62.78 ± 22.1461.06 ± 32.92
PrimaryMedication Adherence Measure (MAM)

The MAM is semi-structured interview specific to pediatrics, conducted with the parent, to obtain an individual score in each module. The score is represented in percentages of the number of required doses. A total summary score can be calculated across all medications, as well as separately. This allows for quantification of the degree of adherence on a continuum.

Time frame:
Baseline to day 100
Reported as:
Mean · Percent
Medication Adherence Measure (MAM)
PercentBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Medication Adherence Measure (MAM)99.25 ± 1.5598.52 ± 2.62
PrimarySystem Usability Scale

The SUS is a 10-item questionnaire routinely used to evaluate the functionality and acceptability of mHealth apps. Items are rated on a 5-point scale and scores range from 0 to 100. A higher score indicates better usability. Reliability and validity have been well established. A score of \> 68% is considered above average.

Time frame:
Exit (Day 100)
Reported as:
Mean · Scores on a scale
System Usability Scale
Scores on a scaleBMT4me 2.0 Intervention Group
System Usability Scale70.00 ± 15.08
PrimaryPosttransplant Perception Survey

The posttransplant perception survey is a self-report clinical assessment tool adapted from the kidney transplant population for this trial. The tool contains 7 questions asking participants to report on their views about their child's health and perceptions post-transplant. Questions are rated on a 5-point Likert scale. The first three questions related to worry about child's health and are considered the "Worry" subscale which ranges from 3 to 15, with higher scores indicating more worry. The second four questions relate to the understanding of child's health and are considered the "Understanding" subscale. Scores range from 4 to 20, where higher scores indicate less understanding.

Time frame:
Baseline (Week 0) to 100 Days Post Transplant
Reported as:
Mean · Scores on a scale
Posttransplant Perception Survey
Scores on a scaleBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Worry Subscale Enrollment (Week 0)8.21 ± 3.128.27 ± 2.20
Understanding Subscale Enrollment (Week 0)5.46 ± 2.325.73 ± 2.07
Worry Subscale Exit (100 Days Post Transplant)7.38 ± 2.426.78 ± 3.01
Understanding Subscale Exit (100 Days Post Transplant)6.05 ± 1.945.52 ± 2.13
PrimaryBarrier Assessment Tool

The Barrier Assessment Tool (BAT) is a self-report clinical assessment tool. The tool contains 14 commonly endorsed barriers with a checkbox next to each item. Domains include logistical issues (e.g., forgetting, inconvenience), ingestion difficulties (e.g., swallowing, taste), efficacy (e.g., feel I don't need it), financial difficulties, regimen characteristics (e.g., too many medications, side effects), and patient-specific issues (e.g., refusal by child, embarrassment). A sum total of the number of barriers is calculated, as well as concordance between caregiver and patient report. In the feasibility study, the average concordance between caregiver and patient report of each barrier (n=48) was 0.299.53 The total barrier score will be used. A sum total of 0 to 14 could be calculated, with higher scores indicating more barriers.

Time frame:
Baseline (Week 0) to 100 Days Post Transplant
Reported as:
Mean · Number of Barriers
Barrier Assessment Tool
Number of BarriersBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Enrollment (Week 0)4.24 ± 2.563.40 ± 1.80
Exit (100 days post-transplant)2.34 ± 1.861.79 ± 1.61
PrimaryCaregiver Satisfaction

Satisfaction will be assessed via semi-structured interviews and an electronic version of the Caregiver Satisfaction Questionnaire with caregivers. Caregivers will be asked for feedback regarding participation in the intervention, benefit, burden, barriers, suggested modifications, and overall satisfaction. Suggested modifications to the app and advice to the healthcare team will also be solicited. Due to the qualitative nature of the interview, caregiver responses cannot be scored but will be coded for themes. Nine questions are included on the Caregiver Satisfaction Questionnaire and responses are on a 1 to 4 Likert scale. A total sum score ranges from 9 to 36, with higher scores indicating more satisfaction.

Time frame:
Exit (Day 100)
Reported as:
Mean · Scores on a scale
Caregiver Satisfaction
Scores on a scaleBMT4me 2.0 Intervention Group
Caregiver Satisfaction27.00 ± 4.19
PrimaryPediatric Quality of Life Inventory (PedsQL) Version 4.0

Caregivers completed the Pediatric Quality of Life Inventory (PedsQL) every three weeks (at week 3, week 6, and week 9). The PedsQL has 4 domains related to physical, emotional, social, and school functioning totaling 23 items. Items are rated on a 3 or 5-point Likert scale. All items (23) are summed to a total PedsQL score. Total scores range from 0 - 100, with higher scores indicating higher quality of life. Versions are based on child age: (a) 5-7, (b) 8-12 and, (c) 13-18 years old.

Time frame:
Week 3, Week 6, and Week 9
Reported as:
Mean · Scores on a scale
Pediatric Quality of Life Inventory (PedsQL) Version 4.0
Scores on a scaleBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Week 373.85 ± 17.7973.72 ± 14.76
Week 676.58 ± 17.7972.77 ± 18.67
Week 977.56 ± 18.2773.00 ± 20.44
PrimaryMedy Remote Patient Management (RPM) Medication Box by Vaica

Medy RPM collects daily data via an NFC reader. Each opening and closing is assumed to reflect an administered and consumed medication dose. This data will be collected monthly from participants as a direct measure of adherence. Electronic monitors contain micro-electronic circuits that date and time-stamp each time the container is opened to remove a dose of medication. Data from the electronic monitors will be downloaded using cloud or computer-based software, at each study visit. An adherence percentage was calculated by dividing the number of doses taken by the number of doses prescribed for each day. All of the electronic monitors have been independently tested for accuracy.

Time frame:
Baseline to day 100
Reported as:
Mean · Percent
Medy Remote Patient Management (RPM) Medication Box by Vaica
PercentBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Medy Remote Patient Management (RPM) Medication Box by Vaica69.34 ± 10.6051.08 ± 8.45
SecondaryMedication Level Variability Index (MLVI)

Medication Level Variability Index (MLVI) measures the variation of tacrolimus levels in the blood of a patient over time. Higher variability has been associated with increased risk of poor outcomes following solid organ transplant, with limited findings suggesting a similar trend in HCT. MLVI is calculated using the standard deviation of three or more medication levels. The range of scores is not consistent, but MLVI typically falls between 0-10, with higher scores indicating higher variability (and therefore higher risk of complications). There are clinically significant cutoff scores for solid organ transplant populations; an MLVI of 3 or higher is generally considered to be a high risk. Both continuous and dichotomous scores were used in this analysis.

Time frame:
Weekly until day 100
Reported as:
Mean · Scores on a scale
Medication Level Variability Index (MLVI)
Scores on a scaleBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Medication Level Variability Index (MLVI)3.87 ± 2.443.59 ± 1.66
SecondaryNumber of Participants With Graft vs. Host Disease (GVHD)

GVHD will be assessed on the international standard acute GVHD grading and staging scale. Provider grading will be per organ system on a 1-4 scale, with an overall score given weekly.

Time frame:
Weekly until day 100
Reported as:
Count of participants · Participants
Number of Participants With Graft vs. Host Disease (GVHD)
ParticipantsBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Number of Participants With Graft vs. Host Disease (GVHD)97
SecondaryNumber of Participants With Readmissions

Readmission rates will be determined by the number of admissions requiring greater than a 24-hour stay within the first 100 days after discharge. Reason for readmission will be recorded and based on the EMR discharge diagnosis. In addition, a sub-analysis of readmissions within the first 30 days after initial discharge post-HSCT will be completed.

Time frame:
Weekly until day 100
Reported as:
Count of participants · Participants
Number of Participants With Readmissions
ParticipantsBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Number of Participants With Readmissions911
PrimaryWisepill

Wisepill is a pillbox that collects data on medication usage through the internet. The Wisepill model utilized was evriMED1000. This data was collected as a direct measure of adherence. The evriMED1000 pillbox recorded when the lid was opened and closed and uploaded data in real time into a cloud-based server, where data was retrieved after study exit.

Time frame:
Baseline to day 100
Reported as:
Mean · Percent
Wisepill
PercentBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Wisepill60.65 ± 26.2760.52 ± 25.63
SecondaryCaregiver Education Level

Caregiver reported education level

Time frame:
Baseline (Week 0)
Reported as:
Count of participants · Participants
Caregiver Education Level
ParticipantsBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
Elementary10
High School1011
Post-High School (Technical or Trade School)20
College610
Graduate/Professional45
Missing10
SecondaryAnnual Household Income

Caregiver reported annual household income

Time frame:
Baseline (Week 0)
Reported as:
Count of participants · Participants
Annual Household Income
ParticipantsBMT4me 2.0 Intervention GroupBMT4me 2.0 Control Group
< $25,00068
$25,001 - $50,00065
$50,001 - $75,00043
$75,001 - $100,00033
$100,001 - $150,00022
> $150,00113
Missing22

Adverse events

Collected over Baseline (Week 0) to study exit (100 days posttransplant). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMT4me 2.0 Intervention Group0/24 (0%)0/24 (0%)0/24 (0%)
BMT4me 2.0 Control Group0/26 (0%)0/26 (0%)0/26 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMT4me 2.0 Intervention GroupBMT4me 2.0 Control GroupTotal
Mean31.83 ± 10.4835.19 ± 10.8833.58 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)BMT4me 2.0 Intervention GroupBMT4me 2.0 Control GroupTotal
Female202444
Male426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMT4me 2.0 Intervention GroupBMT4me 2.0 Control GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American246
White191938
More than one race213
Unknown or Not Reported123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMT4me 2.0 Intervention GroupBMT4me 2.0 Control GroupTotal
Hispanic or Latino112
Not Hispanic or Latino202444
Unknown or Not Reported314
08

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jan 2026, 37 months.

Results were first posted in Oct 2026, 9 months after primary completion.

Of 429 non-industry interventional studies with no phase under Medication Adherence, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's 37 months is above that.

Counting every sponsor, half of 447 studies reached it within 22 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 25, 2022
StartActual
Nov 29, 2022
Primary completionActual
Jan 2, 2026
CompletionActual
Jan 2, 2026
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary completion
Jan 21, 2026→Jan 2, 2026
Oct 27, 2026
Study completion
Jan 21, 2026→Jan 2, 2026
Oct 27, 2026
Primary outcomes
2 edited, 2 time frame changed, 1 added, 4 description edited
What changed in the outcomes
  • EditedPediatric Quality of Life Inventory (PedsQL) versionVersion 4.0Time frame: Week 3, Week 6, and Week 9
  • EditedMedy Remote Patient Management (RPM) medication boxMedication Box by VaicaTime frame: Baseline to day 100
  • AddedWisepillTime frame: Baseline to day 100
  • Time framePosttransplant Perception SurveyBaseline (Week 0) → Baseline (Week 0) to 100 Days Post Transplant
  • Time frameBarrier Assessment ToolBaseline (Week 0) → Baseline (Week 0) to 100 Days Post Transplant
  • DescriptionCaregiver Satisfaction: how it is measured was reworded
  • DescriptionMedication Adherence Measure (MAM): how it is measured was reworded
  • DescriptionPosttransplant Perception Survey: how it is measured was reworded
  • DescriptionSystem Usability Scale: how it is measured was reworded
Oct 27, 2026
Documents
Secondary outcomes
2 edited, 2 added, 2 removed, 1 description edited
What changed in the outcomes
  • EditedNumber of Participants With Graft vs. Host Disease (GVHD)Time frame: Weekly until day 100
  • ChangedBefore ReadmissionsNow Number of Participants With ReadmissionsTime frame: Weekly until day 100
  • AddedCaregiver Education LevelTime frame: Baseline (Week 0)
  • AddedAnnual Household IncomeTime frame: Baseline (Week 0)
  • RemovedDemographic Data FormTime frame: Baseline (Week 0)
  • RemovedMedication Possession Ratio (MPR)Time frame: Monthly until day 100
  • DescriptionMedication Level Variability Index (MLVI): how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary completion Jan 21, 2026→Jan 2, 2026
    Study completion Jan 21, 2026→Jan 2, 2026
    Primary outcomes 2 edited, 2 time frame changed, 1 added, 4 description edited
    What changed in the outcomes
    • EditedPediatric Quality of Life Inventory (PedsQL) versionVersion 4.0Time frame: Week 3, Week 6, and Week 9
    • EditedMedy Remote Patient Management (RPM) medication boxMedication Box by VaicaTime frame: Baseline to day 100
    • AddedWisepillTime frame: Baseline to day 100
    • Time framePosttransplant Perception SurveyBaseline (Week 0) → Baseline (Week 0) to 100 Days Post Transplant
    • Time frameBarrier Assessment ToolBaseline (Week 0) → Baseline (Week 0) to 100 Days Post Transplant
    • DescriptionCaregiver Satisfaction: how it is measured was reworded
    • DescriptionMedication Adherence Measure (MAM): how it is measured was reworded
    • DescriptionPosttransplant Perception Survey: how it is measured was reworded
    • DescriptionSystem Usability Scale: how it is measured was reworded
    Secondary outcomes 2 edited, 2 added, 2 removed, 1 description edited
    What changed in the outcomes
    • EditedNumber of Participants With Graft vs. Host Disease (GVHD)Time frame: Weekly until day 100
    • ChangedBefore ReadmissionsNow Number of Participants With ReadmissionsTime frame: Weekly until day 100
    • AddedCaregiver Education LevelTime frame: Baseline (Week 0)
    • AddedAnnual Household IncomeTime frame: Baseline (Week 0)
    • RemovedDemographic Data FormTime frame: Baseline (Week 0)
    • RemovedMedication Possession Ratio (MPR)Time frame: Monthly until day 100
    • DescriptionMedication Level Variability Index (MLVI): how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05515497
Lead sponsor
Micah Skeens
Responsible party
Micah Skeens (Principal Investigator, Nationwide Children's Hospital) — Sponsor-investigator
First posted
Aug 25, 2022
Start date
Nov 29, 2022
Primary completion
Jan 2, 2026
Completion
Jan 2, 2026
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion